Capricor Sues NS Pharma Over Deramiocel Launch Issues
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 59 minutes ago
0mins
Should l Buy CAPR?
Source: stocktwits
- Legal Action Impact: Capricor has filed a lawsuit against NS Pharma, alleging failure to prepare for the commercial rollout of its DMD therapy Deramiocel, resulting in a 13% drop in after-hours trading, reflecting investor concerns about the company's future.
- Pricing Structure Issues: Capricor claims that the current pricing structure could render Deramiocel commercially unviable under Medicare reimbursement rules, potentially limiting patient access as hospitals and treatment centers may incur losses administering the therapy.
- Launch Preparation Delays: The lawsuit alleges that NS Pharma slowed down launch preparations after the FDA issued a Complete Response Letter, disrupting market access and pricing strategies, which could adversely affect the drug's approval and commercialization.
- Investor Focus on FDA: As the FDA continues its review of Deramiocel, Capricor's shareholders are closely monitoring leadership changes within the agency, with market sentiment becoming extremely bullish amid high message volume, despite the ongoing legal challenges.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CAPR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CAPR
Wall Street analysts forecast CAPR stock price to rise
7 Analyst Rating
7 Buy
0 Hold
0 Sell
Strong Buy
Current: 34.380
Low
45.00
Averages
51.57
High
60.00
Current: 34.380
Low
45.00
Averages
51.57
High
60.00
About CAPR
Capricor Therapeutics, Inc. is a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and prevention of rare diseases. The Company's program is focused on the development and commercialization of a cell therapy technology comprised of cardiosphere-derived cells (CDCs) for the treatment of Duchenne muscular dystrophy (DMD). Its lead product candidate deramiocel (also referred to as CAP-1002), is an allogeneic cardiac-derived cell therapy. CAP-1002 is advancing through Phase III clinical development for the treatment of Duchenne muscular dystrophy (DMD). CAP-1002 demonstrates immunomodulatory, antifibrotic, and regenerative actions specifically tailored for dystrophinopathies and heart disease. It leverages its exosome technology, using its StealthX platform in preclinical development focused on the areas of vaccinology, targeted delivery of oligonucleotides, proteins, and small molecule therapeutics.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Capricor Sues NS Pharma Over Deramiocel Launch Issues
- Legal Action Impact: Capricor has filed a lawsuit against NS Pharma, alleging failure to prepare for the commercial rollout of its DMD therapy Deramiocel, resulting in a 13% drop in after-hours trading, reflecting investor concerns about the company's future.
- Pricing Structure Issues: Capricor claims that the current pricing structure could render Deramiocel commercially unviable under Medicare reimbursement rules, potentially limiting patient access as hospitals and treatment centers may incur losses administering the therapy.
- Launch Preparation Delays: The lawsuit alleges that NS Pharma slowed down launch preparations after the FDA issued a Complete Response Letter, disrupting market access and pricing strategies, which could adversely affect the drug's approval and commercialization.
- Investor Focus on FDA: As the FDA continues its review of Deramiocel, Capricor's shareholders are closely monitoring leadership changes within the agency, with market sentiment becoming extremely bullish amid high message volume, despite the ongoing legal challenges.
See More
FDA Leadership Contender Sparks Market Interest
- FDA Leadership Consideration: Hemmati is reportedly being considered for a leadership role at the FDA's Center for Biologics Evaluation and Research, which could influence the agency's approval strategies for gene and cell therapies, particularly regarding rare disease treatments.
- Drug Approval Perspective: Hemmati stated on social media that FDA approval is merely a safety check, emphasizing patient and physician choice, which may impact investor confidence in Capricor, leading to an 8% decline in its stock on Friday.
- DMD Therapy Decision: Capricor awaits an FDA decision on its DMD therapy, Deramiocel, expected by August 22, with prior clinical trials showing a 54% slowing in upper-limb function decline, potentially affecting the company's future market performance.
- Market Sentiment Analysis: Despite regulatory pressures, retail sentiment for CAPR remains 'bullish', reflecting market expectations for potential rewards tied to clinical trial success, with the stock surging 143% over the past year.
See More
Capricor's Biologics Application Under FDA Review
- FDA Review Progress: Capricor Therapeutics' Biologics License Application is currently under review by the U.S. FDA, with a decision expected on August 22, 2026, following a resumption of review after a Complete Response Letter in July 2025, indicating the company's ongoing commitment to advancing DMD treatments.
- Clinical Trial Highlights: The Phase 3 HOPE-3 trial data for Deramiocel demonstrated a 54% slower decline in upper-limb function and a 91% reduction in cardiac disease progression, suggesting significant potential for improving the quality of life for DMD patients, which may attract increased investor interest.
- Improved Patient Independence: Management highlighted that video assessments showed Deramiocel effectively slowed disease progression in patients' ability to self-feed, a finding that not only holds clinical significance but could also enhance patient independence, thereby boosting market confidence in the therapy.
- FDA Leadership Buzz: The consideration of former Capricor executive Hemmati for a key leadership role at the FDA's Center for Biologics Evaluation and Research could positively impact Capricor's future, particularly in regulatory policies concerning rare disease treatments.
See More
Capricor Presents Phase 3 Data for DMD Therapy Deramiocel
- Clinical Trial Results: Capricor presented data from its Phase 3 HOPE-3 trial of Deramiocel for DMD at the 2026 AAN Annual Meeting, demonstrating statistically and clinically meaningful improvements in upper limb function, marking a potential breakthrough in DMD treatment.
- Evidence of Function Preservation: The study indicated that Deramiocel significantly slowed disease progression in self-feeding abilities, validated through video assessments of home tasks, emphasizing the therapy's critical impact on patient independence and quality of life.
- Regulatory Progress: Capricor's Biologics License Application (BLA) is currently under FDA review, with a target action date of August 22, 2026, which, if approved, would provide new treatment options for DMD patients and further solidify the company's leadership in biotechnology.
- Market Potential: Deramiocel has received Orphan Drug Designation from both the FDA and EMA, along with Regenerative Medicine Advanced Therapy (RMAT) designation, highlighting its significant market potential as Capricor aims to rapidly deliver this innovative therapy to patients in need.
See More
Capricor's Former Executive Considered for FDA Biologics Chief
- FDA Decision Approaches: Capricor is awaiting an FDA decision on its DMD treatment Deramiocel, expected by August 22, which will directly impact the company's market performance and investor confidence.
- Clinical Data Support: The resubmission included results from the Hope-3 trial, showing a 54% slower deterioration in upper-limb function and a 91% slowing of cardiac disease progression, providing strong statistical support for the drug's approval.
- Executive Transition Impact: Former VP Houman Hemmati is being considered for the FDA's Center for Biologics Evaluation and Research, which could improve approval prospects for Capricor and other biotech firms, as reflected by a 1% rise in stock price during premarket trading.
- Market Sentiment Shift: With Hemmati's potential appointment, retail sentiment for Capricor shifted from 'bearish' to 'bullish', with expectations that the stock could exceed $75 upon approval, indicating a positive outlook for the company's future.
See More
Analysts Bullish on Capricor's Treatment Prospects
- FDA Review Resumed: The U.S. FDA has lifted the previously issued Complete Response Letter and resumed the review of the Biologics License Application for Deramiocel, with a decision expected by August 22, 2026, bringing renewed hope for Capricor's treatment prospects.
- Analyst Price Target Increases: B. Riley raised Capricor's price target from $50 to $63 while maintaining a ‘Buy’ rating, reflecting increased confidence in a smooth approval path for Deramiocel ahead of the decision date, with shares expected to rise.
- Positive Market Reaction: Despite Capricor reporting a wider-than-expected loss in its latest earnings call, leading to a 9% drop in shares, Roth Capital analysts view this pullback as a transient market correction and recommend buying, with a target price of $41.
- Strong Cash Position: Piper Sandler increased Capricor's price target from $45 to $58, noting the company ended 2025 with $318 million in cash to fund operations through 2027, indicating a solid financial foundation for future growth.
See More
Capricor Sues NS Pharma Over Deramiocel Launch Issues
- Legal Action Impact: Capricor has filed a lawsuit against NS Pharma, alleging failure to prepare for the commercial rollout of its DMD therapy Deramiocel, resulting in a 13% drop in after-hours trading, reflecting investor concerns about the company's future.
- Pricing Structure Issues: Capricor claims that the current pricing structure could render Deramiocel commercially unviable under Medicare reimbursement rules, potentially limiting patient access as hospitals and treatment centers may incur losses administering the therapy.
- Launch Preparation Delays: The lawsuit alleges that NS Pharma slowed down launch preparations after the FDA issued a Complete Response Letter, disrupting market access and pricing strategies, which could adversely affect the drug's approval and commercialization.
- Investor Focus on FDA: As the FDA continues its review of Deramiocel, Capricor's shareholders are closely monitoring leadership changes within the agency, with market sentiment becoming extremely bullish amid high message volume, despite the ongoing legal challenges.
See More
FDA Leadership Contender Sparks Market Interest
- FDA Leadership Consideration: Hemmati is reportedly being considered for a leadership role at the FDA's Center for Biologics Evaluation and Research, which could influence the agency's approval strategies for gene and cell therapies, particularly regarding rare disease treatments.
- Drug Approval Perspective: Hemmati stated on social media that FDA approval is merely a safety check, emphasizing patient and physician choice, which may impact investor confidence in Capricor, leading to an 8% decline in its stock on Friday.
- DMD Therapy Decision: Capricor awaits an FDA decision on its DMD therapy, Deramiocel, expected by August 22, with prior clinical trials showing a 54% slowing in upper-limb function decline, potentially affecting the company's future market performance.
- Market Sentiment Analysis: Despite regulatory pressures, retail sentiment for CAPR remains 'bullish', reflecting market expectations for potential rewards tied to clinical trial success, with the stock surging 143% over the past year.
See More
Capricor's Biologics Application Under FDA Review
- FDA Review Progress: Capricor Therapeutics' Biologics License Application is currently under review by the U.S. FDA, with a decision expected on August 22, 2026, following a resumption of review after a Complete Response Letter in July 2025, indicating the company's ongoing commitment to advancing DMD treatments.
- Clinical Trial Highlights: The Phase 3 HOPE-3 trial data for Deramiocel demonstrated a 54% slower decline in upper-limb function and a 91% reduction in cardiac disease progression, suggesting significant potential for improving the quality of life for DMD patients, which may attract increased investor interest.
- Improved Patient Independence: Management highlighted that video assessments showed Deramiocel effectively slowed disease progression in patients' ability to self-feed, a finding that not only holds clinical significance but could also enhance patient independence, thereby boosting market confidence in the therapy.
- FDA Leadership Buzz: The consideration of former Capricor executive Hemmati for a key leadership role at the FDA's Center for Biologics Evaluation and Research could positively impact Capricor's future, particularly in regulatory policies concerning rare disease treatments.
See More
Capricor Presents Phase 3 Data for DMD Therapy Deramiocel
- Clinical Trial Results: Capricor presented data from its Phase 3 HOPE-3 trial of Deramiocel for DMD at the 2026 AAN Annual Meeting, demonstrating statistically and clinically meaningful improvements in upper limb function, marking a potential breakthrough in DMD treatment.
- Evidence of Function Preservation: The study indicated that Deramiocel significantly slowed disease progression in self-feeding abilities, validated through video assessments of home tasks, emphasizing the therapy's critical impact on patient independence and quality of life.
- Regulatory Progress: Capricor's Biologics License Application (BLA) is currently under FDA review, with a target action date of August 22, 2026, which, if approved, would provide new treatment options for DMD patients and further solidify the company's leadership in biotechnology.
- Market Potential: Deramiocel has received Orphan Drug Designation from both the FDA and EMA, along with Regenerative Medicine Advanced Therapy (RMAT) designation, highlighting its significant market potential as Capricor aims to rapidly deliver this innovative therapy to patients in need.
See More
Capricor's Former Executive Considered for FDA Biologics Chief
- FDA Decision Approaches: Capricor is awaiting an FDA decision on its DMD treatment Deramiocel, expected by August 22, which will directly impact the company's market performance and investor confidence.
- Clinical Data Support: The resubmission included results from the Hope-3 trial, showing a 54% slower deterioration in upper-limb function and a 91% slowing of cardiac disease progression, providing strong statistical support for the drug's approval.
- Executive Transition Impact: Former VP Houman Hemmati is being considered for the FDA's Center for Biologics Evaluation and Research, which could improve approval prospects for Capricor and other biotech firms, as reflected by a 1% rise in stock price during premarket trading.
- Market Sentiment Shift: With Hemmati's potential appointment, retail sentiment for Capricor shifted from 'bearish' to 'bullish', with expectations that the stock could exceed $75 upon approval, indicating a positive outlook for the company's future.
See More
Analysts Bullish on Capricor's Treatment Prospects
- FDA Review Resumed: The U.S. FDA has lifted the previously issued Complete Response Letter and resumed the review of the Biologics License Application for Deramiocel, with a decision expected by August 22, 2026, bringing renewed hope for Capricor's treatment prospects.
- Analyst Price Target Increases: B. Riley raised Capricor's price target from $50 to $63 while maintaining a ‘Buy’ rating, reflecting increased confidence in a smooth approval path for Deramiocel ahead of the decision date, with shares expected to rise.
- Positive Market Reaction: Despite Capricor reporting a wider-than-expected loss in its latest earnings call, leading to a 9% drop in shares, Roth Capital analysts view this pullback as a transient market correction and recommend buying, with a target price of $41.
- Strong Cash Position: Piper Sandler increased Capricor's price target from $45 to $58, noting the company ended 2025 with $318 million in cash to fund operations through 2027, indicating a solid financial foundation for future growth.
See More
